Outcomes
SARS-CoV-2-specific RBD
ADVERSE REACTIONS, SECONDARY, ADVERSE EVENTS, CHRONIC DISEASES
The primary outcomes were the occurrence of solicited local or systemic adverse reactions and assessments of geometric mean concentration (GMC)/geometric mean titer (GMT), seroconversion/seropositive rates, and geometric mean fold increase (GMFI) of antibodies that bind SARS-CoV-2-specific RBD and pseudovirus-neutralizing antibodies against Omicron BA.4/5 on day 14 post-booster dose. Safety secondary outcomes included information on unsolicited adverse events for 28 days after immunization and serious adverse events recorded throughout the whole follow-up visits. Immunological secondary outcomes included the above indices of humoral immune responses to vaccination at 28 and 90 days after vaccination. The exploratory outcomes were analyses of influencing factors (including age, sex, BMI, and chronic diseases) to adverse reactions and immunogenicity.